Avapritinib (Ayvakit) has been approved for adults with gastrointestinal stromal tumors (GIST) whose tumors have an alteration in a portion of the PDGFRA gene called exon 18. The approval applies to those whose tumors cannot be removed with surgery or have spread.
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2Uvxwlu
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2Uvxwlu